Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis

Fumio Matsumoto, Takeo Imai, Akira Saito, Masumi Tomisawa, Yohmei Hiraga, Mitsuhide Ohmichi, Masao Tamura, Kazuki Konishi, Hitoshi Kobayashi, Kotaro Oizumi, Akira Watanabe, Kiyoshi Konno, Hideo Arai, Izumi Hayashi, Koichiro Nakata, Masayuki Noguchi, Naohiko Chonabayashi, Tatsuo Nakatani, Hiroyuki Kobayashi, Hiroaki TakedaHiroshi Oshitani, Junzaburo Kabe, Koichiro Kudo, Shigeki Odagiri, Kaneo Suzuki, Shigeo Takizawa, Masaaki Arakawa, Koichi Wada, Masanaga Takato, Shigeyuki Hoshino, Hajimu Takeda, Osamu Sekine, Yasutoshi Suzuki, Kaoru Oyama, Fumio Miki, Rinzo Soejima, Niro Okimoto, Toshiharu Matsushima, Makoto Kimura, Kohei Hara, Yasumasa Dotsu, Hironobu Koga, Shigeru Kohno, Masahiro Yatsugi, Kazuto Hiratani, Kenji Kawano, Takeshi Ishizaki, Keizo Matsumoto, Hirofumi Tanaka, Masaru Nasu, Yoichiro Goto, Jun Goto, Hideaki Shigeno, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Nobuya Ogawa

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    We performed a dose-finding study on cefetamet pivoxil (CEMT-PI), a new oral cephem, in the treatment of acute exacerbation of chronic bronchitis, by a multicenter well-controlled comparative study. CEMT-PI was orally administered at 500 mg b. i. d., 750mg t. i. d. or 1,000mg b. i. d. The clinical efficacy rate assessed by committee was 61.8% (21/34) in the 500mg group, 67.6% (23/34) in the 750mg group and 72.7% (24/33) in the 1,000mg group. There were no significant differences among the three groups. The bacteriological eradication rate was 81.3%(13/16) in the 500mg group, 78.6% (11/14) in the 750mg group and 66.7% (8/12) in the 1,000mg group. There were no significant differences among the three groups. Except for the cases infected with Staphylococcus aureus and Pseudomonas aeruginosa, bacteriological eradication was 11/13 in the 500mg group, 10/12 in the 750mg group and, 7/8 in the 1, 000mg group. There were no significant differences among the three groups. The incidence of side effects was 11.1% (4/36) in the 500mg group, 2.8%(1/36) in the 750mg group and 2.7% (1/37) in the 1, 000mg group. There were no significant differences among the three groups. We conclude from our results that 1, 000mg b. i. d. is the optimal dose of CEMT-PI in the treatment of acute exacerbation of chronic bronchitis.

    Original languageEnglish
    Pages (from-to)198-209
    Number of pages12
    JournalChemotherapy
    Volume38
    DOIs
    Publication statusPublished - 1990

    Keywords

    • CEMT-PI
    • Cefetamet pivoxil

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Dose-finding study on cefetamet pivoxil in acute exacerbation of chronic bronchitis'. Together they form a unique fingerprint.

    Cite this